Communiqués Apogee Therapeutics, Inc.

Actions

APGE

US03770N1019

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 21/06/2024			Varia. 5j.	Varia. 1 janv.
38 ^USD	-0,13%		-7,63%	+36,01%

28/05	Apogee Therapeutics, Inc. nomme Lisa Bollinger à son conseil d'administration	CI
15/05	Apogee annonce le dosage du premier patient de l'essai de phase 2 sur la dermatite atopique avec APG777, un nouvel anticorps antiIL-13 à demi-vie prolongée administré par voie sous-cutanée pour le traitement de la dermatite atopique et d'autres maladies inflammatoires.	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD	28/05	AQ
Apogee Therapeutics to Participate in Upcoming June Investor Conferences	23/05	AQ
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15/05	AQ
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results	13/05	AQ
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference	06/05	AQ
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases	25/03	AQ
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million	12/03	AQ
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering	08/03	AQ
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering	05/03	AQ
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	05/03	AQ
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days	05/03	AQ
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024	04/03	AQ
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	02/01	AQ
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results	13/11	AQ
Apogee Therapeutics to Participate in Upcoming November Investor Conferences	30/10/23	AQ
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress	27/09/23	AQ
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day	14/09/23	AQ
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology Biological Therapeutics	07/09/23	AQ
Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics	29/08/23	PR
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results	28/08/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Apogee Therapeutics, Inc.

Actions

APGE

US03770N1019

Communiqués

Filtres